Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Marcus

Pediatric Allergy/Immunology Brooklyn, NY Medical Doctor

NPI 1134114192 CMS profile 323731

948 48Th St, Brooklyn, NY 11219

Open in the dashboard

General payments

$1,310,787

1,423 records reported · program years 2019–2025

Research payments

$10,912

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Marcus of Brooklyn, NY is reported in the CMS Open Payments database as having received $1,310,787 across 1,423 general payments and $10,912 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247,963 228
2024 General $198,568 208
2023 General $224,414 254
2022 General $214,587 242
2021 General $145,155 156
2020 General $75,584 72
2019 General $204,517 263
2019 Research $10,912 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Marcus
  • Pediatric Allergy/Immunology median
  • Middle half of Pediatric Allergy/Immunology
  • National median

In program year 2025, general payments to Michael Marcus were reported at $247,963. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.

Show as a table
Year Michael Marcus Pediatric Allergy/Immunology median Middle half National median
2019 $204,517 $325 $92–$1,399 $163
2020 $75,584 $144 $66–$2,490 $114
2021 $145,155 $357 $95–$2,633 $132
2022 $214,587 $385 $125–$2,259 $149
2023 $224,414 $470 $121–$2,946 $160
2024 $198,568 $317 $125–$2,583 $164
2025 $247,963 $361 $125–$2,493 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,069,905 1,075 payments
  2. Regeneron Healthcare Solutions, Inc. $131,291 162 payments
  3. Amgen Inc. $37,735 44 payments
  4. ARS Pharmaceuticals Operations, Inc. $23,460 28 payments
  5. Sobi, Inc $17,827 31 payments
  6. Regeneron Pharmaceuticals, Inc. $15,564 9 payments
  7. OptiNose US, Inc. $7,488 12 payments
  8. Genentech USA, Inc. $6,370 14 payments
  9. CSL Behring $223 4 payments
  10. Genzyme Corporation $205 11 payments
  11. Other $719 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $999,239 364 payments
  2. Travel and Lodging $146,760 507 payments
  3. Consulting Fee $124,644 56 payments
  4. Food and Beverage $34,228 492 payments
  5. Honoraria $5,700 1 payment
  6. Education $216 3 payments
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $442,030 397 payments
  2. TEZSPIRE Respiratory $309,366 320 payments
  3. FASENRA Respiratory $236,157 244 payments
  4. DUPIXENT Inflammation And Immunology $93,247 125 payments
  5. TEZSPIRE Inflammation $32,093 38 payments
  6. NEFFY $23,460 28 payments
  7. DUPIXENT Immunology And Inflammation $21,134 14 payments
  8. AIRSUPRA $17,916 26 payments
  9. SYNAGIS $17,827 31 payments
  10. Xhance $7,488 12 payments
  11. Other $7,672 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $7,912 2 payments
  2. AstraZeneca AB $3,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Allergy/ Immunology: 449

Drug cost

$2,764

Median for Allergy/ Immunology: $169,700

Branded share of claims

100%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $2,379
Albuterol Sulfate Hfa Albuterol Sulfate Brand 15 $385

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$93,629 — —
FASENRA
$77,181 — —
DUPIXENT
$17,205 — —
Haegarda
$148 — —
TAKHZYRO
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,426 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Allergy/Immunology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record